Euro-Phospholipid on Line

Official Web-site of the "European Forum on Antiphospholipid Antibodies"

MULTICENTRE STUDIES

PRIMARY THROMBOPROPHYLAXIS OF APL-POSITIVE SUBJECTS (ALIWAPAS TRIAL)


 

COORDINATORS

 

Munther A Khamashta MD FRCP PhD

Lupus Research Unit, The Rayne Institute, King’s College London School of Medicine, St Thomas’ Hospital, London, UK

 

PROJECT

 

The controversy concerning whether or not prophylactic treatment is indicated for patients with aPL who have no history of thrombosis remains unresolved. Although low-dose aspirin (75-100mg daily) has been considered to be a logical first option, the Physician Health Study showed that low-dose aspirin (325mg daily) in men with aCL did not protect against deep venous thrombosis or pulmonary embolus. In contrast, hydroxychloroquine may be protective against the development of thrombosis in aPL-positive patients with SLE.

A prospective, randomized clinical trial comparing low-dose aspirin alone with low-dose aspirin plus low-intensity warfarin (INR~1.5) in patients with aPL who have never had thrombosis is currently under way in the United Kingdom. Inclusion criteria were 1) aPL positive (Sapporo criteria); 2) SLE patients without thrombosis but persistently positive aPL; 3) obstetric APS (Sapporo criteria), without previous history of thrombosis.

Although 1000 patients were originally envisaged to be included in this study, only 233 patients were recruited during a 4-year period. Of them, 167 were randomized by minimization in order to achieve closely balanced treatment groups and 66 patients were included in the observational arm (these patients did not accept to be randomized but consented to be followed-up using the same protocol as the randomized patients).

The Steering Committee and Data Monitoring Committee decided to stop recruitment (January 2005) and allowed for follow up for at least 5 years. So far, 15 thrombotic events have occurred. Blood samples from all patients are being collected every six months at their follow-up visits. Surrogate laboratory markers are currently being investigated.

For additional information and applications, please e-mail: munther.khamashta@kcl.ac.uk


Web contens: EWPSLE Info Desk.

 

Last updated: 17 November 2005